At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REGN Regeneron Pharmaceuticals
Market Closed 10-16 16:00:00 EDT
790.74
-5.60
-0.70%
盘后792.00
+1.26+0.16%
19:58 EDT
High805.68Low787.32Vol653.73K
Open803.01D1 Closing796.34Amplitude2.30%
Mkt Cap81.41BTradable Cap78.19BTotal Shares102.95M
T/O518.33MT/O Rate0.66%Tradable Shares98.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Bellwether Stocks Movement  ·  10-17 16:33
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Regeneron Pharmaceuticals (REGN) Could Be 7% Undervalued After Libtayo And Pasatru Updates
Simply Wall St.  ·  10-18 14:38
Regeneron Pharmaceuticals (REGN) Could Be 7% Undervalued After Libtayo And Pasatru Updates
From Algorithms To Oncology: Why IAM Jumped On Day One
Bellwether Stocks Movement  ·  10-16 21:50
From Algorithms To Oncology: Why IAM Jumped On Day One
Regeneron Says EMA Panel Recommends Approval of Updated Dosing Regimen for Libtayo
MT Newswires Live  ·  10-16 19:34
Regeneron Says EMA Panel Recommends Approval of Updated Dosing Regimen for Libtayo
Libtayo® (Cemiplimab) Recommended for EU Approval by the Chmp for Updated Dosing Regimen Across All Approved Cancer Types
THOMSON REUTERS  ·  10-16 19:00
Libtayo® (Cemiplimab) Recommended for EU Approval by the Chmp for Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals - European Commission Expected to Decide on Libtayo Dosing Regimen in Coming Months
THOMSON REUTERS  ·  10-16 19:00
Regeneron Pharmaceuticals - European Commission Expected to Decide on Libtayo Dosing Regimen in Coming Months
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Sector Pulse  ·  10-16 09:02
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Regeneron Pharma Price Target Raised to $978.00/Share from $660.00 by UBS
Dow Jones  ·  10-16 05:33
Regeneron Pharma Price Target Raised to $978.00/Share from $660.00 by UBS
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-16 04:43
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Regeneron Co-Chief Scientific Officer Andrew J. Murphy Reports $12.9 Million Disposal of Common Shares
Reuters  ·  10-16 04:03
Regeneron Co-Chief Scientific Officer Andrew J. Murphy Reports $12.9 Million Disposal of Common Shares
Regeneron Pharmaceuticals Shares Rise After UBS Upgrade
MT Newswires Live  ·  10-16
Regeneron Pharmaceuticals Shares Rise After UBS Upgrade
Sanofi Signs Letter of Intent With Canadian Drug Alliance for Dupixent in Four Additional Indications
MT Newswires Live  ·  10-16
Sanofi Signs Letter of Intent With Canadian Drug Alliance for Dupixent in Four Additional Indications
Sanofi and Pcpa Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care
THOMSON REUTERS  ·  10-16
Sanofi and Pcpa Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care
Top Calls on Wall Street: Nvidia, CoreWeave, Walmart, Crocs, CarMax, Regeneron and More
Tiger Newspress  ·  10-15
Top Calls on Wall Street: Nvidia, CoreWeave, Walmart, Crocs, CarMax, Regeneron and More
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Tiger Newspress  ·  10-15
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Regeneron Pharmaceuticals, Inc. : UBS Raises to Buy from Neutral
THOMSON REUTERS  ·  10-15
Regeneron Pharmaceuticals, Inc. : UBS Raises to Buy from Neutral
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.58% in Regular Trading, UBS Resumes Coverage With a Buy Rating
Market Focus  ·  10-15
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.58% in Regular Trading, UBS Resumes Coverage With a Buy Rating
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $968 From $972
MT Newswires Live  ·  10-15
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $968 From $972
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-15
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.09% in Regular Trading, Pasatru long-term trial data support post-approval outlook
Market Focus  ·  10-15
Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.09% in Regular Trading, Pasatru long-term trial data support post-approval outlook

Introduction

Company Name.
Regeneron Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Issue price:
--